Itaconix plc
ITACONIX PLC
("Itaconix" or the "Company")
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
Our most successful year into a new stage of development and growth
Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers, is delighted to announce its Preliminary Results for the year ended 31 December 2025.
Financial and Operational Highlights
|
|
2025
$’000 |
2024 (Restated) $’000 |
2023
$’000 |
2022
$’000 |
2021
$’000 |
|
Revenue |
10,499 |
6,503 |
7,866 |
5,600 |
2,596 |
|
Gross profit |
3,642 |
2,260 |
2,437 |
1,487 |
700 |
|
Gross profit margin |
34.7% |
34.7% |
31.0% |
26.6% |
27.0% |
|
Adjusted EBITDA1[1] |
(600) |
(1,778) |
(925) |
(1,395) |
(1,640) |
|
Cash used from operating activities |
(1,222) |
(2,753) |
(1,923) |
(219) |
(2,023) |
|
Net cash and investments at year-end |
4,391 |
6,734 |
10,023 |
597 |
683 |
1 Adjusted for interest, tax, depreciation, amortisation, share based payment charge, and exceptional items.
- Record annual revenues surpassed $10m for the first time, reflecting 61% year-on-year growth.
- Annual gross profit surpassed $3m for the first time. Maintained overall gross profit margin of 35%, with gross profit margin in core Itaconix Performance Ingredients business at 41%.
- Adjusted EBITDA losses improved to $0.6m, from $1.8m in 2024.
- Net losses declined to $1.4m in 2025 from $2.0m in 2024.
- Ended the year with strong working capital position for growth.
- Itaconix® Performance Ingredients and SPARX™ Formulated Solutions businesses on strong paths towards profitable long-term growth.
- Development of BIO*Asterix® specialty itaconate monomers and resins business into large new revenue opportunity. Launch of BIO*Asterix® ecommerce site (www.bioasterix.com) in July 2025.
- Leveraged the performance advantages of scale inhibitors through the SPARX™ Formulated Solutions program, to develop new unit dose detergent formulations for 17 North American brands.
- Several new ingredients in pre-commercial or early commercial stages.
- The Company has entered 2026 with strong order momentum and a growing pipeline of projects. Management’s expectations for the year to 31 December 2026 remain unchanged, with strong forecast revenue growth and positive adjusted EBITDA*.
* The Board believes the current market expectations for the year ended 31 December 2026 are as follows: Revenue - $13.3m, Adjusted EBITDA - $0.3m, Net cash - $3m
Commenting on the outlook, John R. Shaw, CEO of Itaconix said:
“Achieving $10.5m in revenues is a major milestone towards our goal of developing a large, highly profitable, capital efficient specialty ingredient company.
We sell proprietary ingredients that consumer product brands increasingly want to use for their safety, performance, affordability, and sustainability. Our commercial traction, diverse revenue base, customer project pipeline, and production capacity put us in position for continued growth into a solid foundation of profitability for both generating shareholder value and pursuing additional revenue horizons.
Reaching this position while navigating geopolitical turmoil underscores the strength of our business and the resilience of our supply chain, our operations, and our organisation to global uncertainties.
We are off to a strong start in 2026 and remain confident that we will meet the management expectations, including a clear path to positive adjusted EBITDA in 2026.”
- Ends -
|
Itaconix plc John R. Shaw / Laura Denner |
+1 603 775-4400 |
|
Rosewood John West / Llewellyn Angus / Lily Pearce |
+44 (0)20 7653 8702 |
|
Canaccord Genuity - Nominated Adviser and Sole Broker Adam James / Harry Pardoe |
+44 (0) 20 7523 8000 |
About Itaconix
Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.
Report & Accounts and Notice of AGM
The Company’s statutory accounts for the year ended 31 December 2025, together with a Notice of Annual General Meeting, are available on the Company’s website (www.itaconix.com) and posted to shareholders on 24 March 2026. Copies will also be available at the Company’s registered office, Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London EC4R 3TT, United Kingdom.
The Annual General Meeting is due to be held at 14:00 BST on 14 May 2026 at Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London EC4R 3TT, United Kingdom.
1 Adjusted for interest, tax, depreciation, amortisation, share based payment charge, and exceptional items.
2 Unaudited revenues by reporting period.
About Itaconix
Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.
